Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sunesis cancer news

SNSS restructured and reduced headcount by 35 (25%) to 108 to focus on its clinical programs and extend its financial resources

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE